Home › Research › Risk factors
Progression of clinical markers in prodromal Parkinson's disease and dementia with Lewy bodies: a multicentre study
Joza S, Hu MT, Jung KY, Kunz D, Stefani A, Dušek P, Terzaghi M, Arnaldi D et al.. Brain : a journal of neurology, 2023-08-01
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Overall, 1160 subjects were followed over an average of 3.3 ± 2.2 years. Finally, while phenoconverters showed overall greater progression than non-converters in motor, olfactory, cognitive and certain autonomic markers, the only robust difference in progression between Parkinson's disease and dementia with Lewy bodies phenoconverters was in cognitive testing. These findings provide optimized clinical end points and sample size estimates to inform future neuroprotective trials.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Joza, S., Hu, M. T., Jung, K. Y., Kunz, D., Stefani, A., Dušek, P., et al. (2023). Progression of clinical markers in prodromal Parkinson's disease and dementia with Lewy bodies: a multicentre study. Brain : a journal of neurology. https://doi.org/10.1093/brain/awad072
Vancouver
Joza S, Hu MT, Jung KY, Kunz D, Stefani A, Dušek P, et al. Progression of clinical markers in prodromal Parkinson's disease and dementia with Lewy bodies: a multicentre study. Brain : a journal of neurology. 2023. doi:10.1093/brain/awad072. PMID: 36881989.
BibTeX
@article{joza2023-36881989,
author = {Joza, S. and Hu, M. T. and Jung, K. Y. and Kunz, D. and Stefani, A. and Dušek, P. and Terzaghi, M. and Arnaldi, D. and others},
title = {{Progression of clinical markers in prodromal Parkinson's disease and dementia with Lewy bodies: a multicentre study}},
journal = {Brain : a journal of neurology},
year = {2023},
doi = {10.1093/brain/awad072},
pmid = {36881989},
url = {https://doi.org/10.1093/brain/awad072}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- Overall, 1160 subjects were followed over an average of 3.3 ± 2.2 years.
- Finally, while phenoconverters showed overall greater progression than non-converters in motor, olfactory, cognitive and certain autonomic markers, the only robust difference in progression between Parkinson's disease and dementia with Lewy bodies phenoconverters was in cognitive testing.
- These findings provide optimized clinical end points and sample size estimates to inform future neuroprotective trials.
New to this subject? Start with our plain-English guide: Risk factors, ranked →
Study details
- Participants1,160
- Evidence strengthHigh
How this study scored 61/100
Published in a leading specialty journal. Scored zero for study design, effect reported and randomized / blinded because the record does not state it. We have no data on journal's citation record, times cited, citations per year, impact for its field and year, cited by studies here, still being cited, senior author's track record and institution's track record, so those were left out: it earned 37 of the 61 points we could judge it on, which is 61 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 9 / 10 | Tier 2 — leading specialty journal (Brain : a journal of neurology) |
| Journal's citation record | — / 4 | No journal record from OpenAlex — left out of this score |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 5 / 5 | Rated “high” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 3 / 5 | 2023 — within 6 year(s) of the newest study here |
| Sample size | 3 / 4 | 1,160 participants |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | — / 7 | No citation count (not found in OpenAlex) — left out of this score |
| Citations per year | — / 5 | No citation count or no year — left out of this score |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | — / 6 | Not yet checked against this library's citation graph — left out of this score |
| Still being cited | — / 4 | No yearly citation counts — left out of this score |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multicenter collaboration | 2 / 3 | PubMed indexes it as a multicentre study |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 36881989) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Points | 37 / 61 | Scored on 12 of 20 parts. We have no data for the rest, so they are left out: 37 of the 61 points we could judge it on is 61 out of 100. |
| Total | 61 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.
Related
Studies in the library that share something with this one. The line above each title says what.
Related studies in Risk factors from nearby years
Also tagged “prodromal-parkinson”
2 studies in the library carry the topic tag “prodromal-parkinson”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 2 tagged studies.